Company profile: Lengo Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical solutions focused on discovering and developing cancer treatments, including AYVAKIT/AYVAKYT (avapritinib) for systemic mastocytosis and gastrointestinal stromal tumors with PDGFRA exon 18 mutations. Offers clinical trials, a U.S. patient support program for access and affordability, and a scientific platform to develop highly selective medicines for mast cell disorders and cancer.
Products and services
- AYVAKIT/AYVAKYT (avapritinib): A mutation-specific therapy commercialized in the U.S. and Europe, indicated for systemic mastocytosis and gastrointestinal stromal tumors with PDGFRA exon 18 mutations
- Scientific Platform: Develops highly selective medicines targeting difficult-to-drug targets in mast cell disorders and cancer, identifying under-addressed mutations and enabling practitioners and pharma to target oncology driver mutations
- Clinical Trials: Conducts experimental studies to test the safety and efficacy of new drugs, supplying patients with access to experimental treatments
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Lengo Therapeutics
Novelos Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical research, development, and commercialization focused on oxidized glutathione.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novelos Therapeutics company profile →
Fabrus
HQ: United States
Website
- Description: Provider of functional therapeutic monoclonal antibody discovery and development targeting challenging cell surface proteins, including GPCRs and ion channels, supported by a unique antibody discovery platform and multiple preclinical lead candidates against important cancer targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fabrus company profile →
AdnaGen
HQ: Germany
Website
- Description: Provider of molecular genetic diagnostic testing systems for medical and clinical research laboratories, offering AdnaTest kits with reagents for immunomagnetic selection, mRNA isolation, and multiplex RT-PCR for tumor diagnostics, and focusing on genetic pre-disposition.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AdnaGen company profile →
Empirica Therapeutics
HQ: Canada
Website
- Description: Provider of therapeutic drugs focused on adoptive immunotherapies targeting aggressive, treatment-resistant cancers, including glioblastoma and brain metastasis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Empirica Therapeutics company profile →
TORL Biotherapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TORL Biotherapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Lengo Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Lengo Therapeutics
2.2 - Growth funds investing in similar companies to Lengo Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Lengo Therapeutics
4.2 - Public trading comparable groups for Lengo Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →